TOMI Q2: Sales Collapse 66% YoY; Services Growth, Cash Crunch and Going‑Concern Risk

TOMI Environmental Solutions, Inc. (OTCMKTS: TOMZ) - Quick update from the Q2 2025 10‑Q

Bottom line: The business is winning strategic contracts and growing services, but product sales plunged year‑over‑year, cash is tight and management flags a going‑concern plus material internal control weaknesses. Below are the facts and a straight‑forward read on the income statement.

Key facts and headline numbers (as reported)
* Sales, net (three months ended June 30, 2025): $1,031,115 (Q2 2024: $3,013,392).
* Sales, net (six months): $2,607,673 (2024: $4,127,479).
* Gross profit (Q2): $677,124 (Q2 2024: $1,854,516) - gross margin ~66% vs ~62% prior year.
* Net loss (Q2): $(1,237,516); Net loss (six months): $(1,493,109).
* Basic loss per share (Q2): $(0.06); six months: $(0.07).
* Cash & cash equivalents (June 30, 2025): $569,450.
* Accounts receivable, net: $1,054,071. Inventories, net: $3,267,460 (inventory reserve $988,108).
* Deferred revenue: $719,235; sales order backlog reported ≈ $1.4M (MD&A).
* Convertible notes, gross: $3,035,000; convertible notes, net: $2,781,730. Proceeds from issuance in H1 2025: $435,000.
* Allowance for credit losses (June 30, 2025): $1,368,701 (Dec 31, 2024: $2,229,977).
* Total assets: $8,475,950; Total liabilities: $5,819,120; Total shareholders' equity: $2,656,830.
* Shares issued & outstanding (Aug 12, 2025): 20,075,205.
* Other income (one‑time ERC): $534,912 recorded in H1 2025.
* Company disclosed "substantial doubt" about going concern and a material weakness in internal control over financial reporting.

What's happening inside the company - operational & strategic points
* Product sales collapsed: product revenue for Q2 fell to $653,000 from $2,728,000 a year earlier (‑76% YoY) - customers deferred capex, per MD&A.
* Services gaining traction: service & training revenue rose to $378,000 in Q2 (up 33% YoY) and $955,000 YTD (up 46% YTD) - management is pushing recurring/service revenue growth.
* Backlog & pipeline: recognized revenue + deferred revenue + backlog reported ≈ $4.6M (Aug 7, 2025), with ~$2M in active negotiations; marquee wins include a ~$450k university CES contract, NASA deployment and an OEM partnership (PBSC).
* Cost control mixed: selling expenses fell materially (Q2 selling expense $240,462 vs $366,265 prior year), but professional fees and credit loss expense increased.
* Capital structure and liquidity: raised convertible notes (H1 proceeds $435k); cash used in operating activities (six months) $(463,302); working capital down to $2.81M - cash runway limited given recurring operating losses.
* Governance & controls: new CFO appointed (David Vanston, May 30, 2025) and Nasdaq minimum bid compliance regained in July 2025, but company reports material weaknesses and remediation plans are in progress.

Income statement - positives
* Gross margin improved to ~66% in Q2 2025 (from ~62% in Q2 2024), indicating better product/service mix and higher relative contribution from higher‑margin services.
* Service revenue growth (33% Q2, 46% YTD) supports shift toward recurring, higher‑visibility revenue streams.
* Cost discipline in selling/marketing reduced selling expenses materially vs prior year.

Income statement - negatives / red flags
* Large revenue decline: total revenue down 66% YoY for Q2 and 37% YTD - product demand volatility is the primary driver.
* Operating loss widened: operating loss for six months $(1,887,154) vs $(1,104,664) prior year (per condensed statements), reflecting persistent SG&A and non‑cash charges.
* Significant credit‑risk volatility: material credit loss expense and a large allowance movements - allowance for credit losses still sizeable ($1.37M) and credit loss expense affected operating results.
* One‑time items mask recurring performance: $534,912 of ERC other income in H1 materially improved "other income" but is non‑recurring.
* Cash & going concern: only $569k cash on hand, continued operating losses and an accumulated deficit of $55.8M - management explicitly states substantial doubt about continuing as a going concern without additional financing.
* Potential dilution: convertible debt, warrants and options represent several million potential shares (management cites ~5.9M potential shares outstanding at June 30, 2025) - conversion could dilute existing holders.

Near‑term catalysts and risks
* Catalysts: pipeline conversion of ~$1.4M backlog + active $2M negotiations, OEM partnership deliveries (Q4 2025), increased service demand (life sciences & food safety) and IP strength (patents/trademarks).
* Risks: macro capex delays (tariffs / supply chain uncertainty), concentrated customer/vendor exposures, need to raise capital (equity/debt) on acceptable terms, and remediation of internal control weaknesses to restore investor confidence.

Bottom line for investors / watchers
* TOMZ has product and IP momentum with growing service revenue and notable contract wins, but the income statement shows a meaningful revenue pullback driven by deferred capital spending. Liquidity and credit‑related allowances plus control weaknesses are the immediate issues - the company needs successful backlog conversion and additional financing (or sustained cash generation from services) to remove the near‑term going‑concern cloud.

If you want, I can convert these points into a 1‑page investor note, a short headline press piece, or a deeper KPI table (margins, cash‑runway scenarios and dilution modeling).